Skip to main content

Data Explorer

Research historical outbreak investigations and the full recall archive, with charts, trends, and advanced filters. Looking for what's happening right now instead? See current Health Alerts.

Recall totals

All FDA and USDA recalls in Public Health Trace, June 2012 to October 2026.

37,238
Total recall recordsAll FDA and USDA recalls in Public Health Trace
9,844
Class I recallsReasonable probability of serious health consequences
24,383
Class II recallsTemporary or medically reversible health consequences
2,897
Class III recallsNot likely to cause adverse health consequences

Quick insights

A snapshot of the most notable patterns across all recorded FDA and USDA recalls.

Most recalled product100 vegetarian Fenugreek Capsules 90 count, 600mg, packaged in 150cc Amber Glass Packer with White Polypropylene Cap. 53 recalls
Most common hazardLack of Assurance of Sterility 2,084 recalls
Most affected stateHawaii 200 recalls mention this state

Download matching recalls as CSV

CSV exports include up to 5,000 matching rows (applying your current filters), not the full dataset if it's larger.

Filters
Recall details
Location
Date range
Sort results
Clear filters
Metric
View
Recalls announced by month (Year to date)

A chart of recalls grouped by month.

Download CSV

Source: FDA and USDA public dataLast updated

Summary (Year to date)

  • 1,739 recalls have been announced year to date.
  • Sep 2026 was 15% higher than the previous complete period (Aug 2026: 182).
  • The highest complete period was Jun 2026 (300).
  • Oct 2026 is incomplete and not included in the figures above.
  • Complete data
  • Incomplete
Recalls by class

A bar chart of the total number of recalls in this dataset by recall class.

Recalls by class
ClassRecalls
Class II24,383
Class I9,844
Class III2,897
Not Yet Classified2
Download CSV
Recalls by class
ClassRecalls
Class II24,383
Class I9,844
Class III2,897
Not Yet Classified2

Showing 21,381–21,400 of 22,209 recalls

FDA Recall OngoingHistorical recordClass II

Glutathione 200 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Gentamicin Sulfate 80 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Gentamicin 80 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Gentamicin 300 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Gentamicin 0.3% Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Gaba 50 mg/Mag Sulfate 50 mg/Taurine/Theanine 50 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Furosemide 50 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Fluphenazine 25 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Estradiol Cypionate 10 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Enrofloxacin 20 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Doxapram 20 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Disodium EDTA Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Diphenhydramine 50 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Diclazuril 10 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Dextrose 50% Solution, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Dexpanthenol 250 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Dexamethasone Sodium Phosphate 6 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Detomidine w/Xylazine 100 mg/mg Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Detomidine 10 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Deslorelin 15 mg vial, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

Data last updated:

Recall records are summarized from official FDA and USDA sources. Notices may be updated, reclassified, terminated, or withdrawn. Always review the linked official notice for the most current instructions. Read the full medical disclaimer.